Open AccessNormalization of long-term quality of life in Crohn�s disease patients receiving ustekinumab
Author(s) -
Miquel Marquès-Camí,
Virginia Robles Alonso,
Natalia Borruel,
Claudia Herrera de Guise,
L Mayorga Ayala,
Francesc Casellas
Publication year - 2020
Publication title -
revista española de enfermedades digestivas/revista española de enfermedades digestivas
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.331
H-Index - 38
eISSN - 2340-4167
pISSN - 1130-0108
DOI - 10.17235/reed.2020.6941/2020
Subject(s) - medicine , ustekinumab , crohn's disease , observational study , disease , quality of life (healthcare) , gastroenterology , adalimumab , nursing
ustekinumab is a fully human monoclonal antibody against IL-12/23, approved for induction and maintenance treatment of Crohn's disease (CD). Real-life data shows its true effectiveness in terms of clinical and endoscopic response. However, there is little information regarding health-related quality of life (HRQoL) in CD patients receiving ustekinumab. The main aim of this study was to define long-term clinical remission and HRQoL normalization. The clinical predictive factors of clinical remission were investigated as a secondary aim.